LN:MPH Mereo BioPharma Group plc

Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease. Mereo BioPharma Group plc was founded in 2015 and is headquartered in London, the United Kingdom.This company has ADRs that trade in the U.S. as the symbol MREO.

26.50 GBP
As of 12/17/2020


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  United Kingdom
IPO date:  01/01/1900
Stock exchange:    London Stock Exchange
Exchange country:   United Kingdom
Market cap:   89,759,200 GBP
Current dividend yield:   0.00%
CUSIP:    
ISIN:        GB00BZ4G2K23
Sedol:      

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy